While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK (LSE: GSK) has reported a 7% increase in full-year revenue for 2024, reaching £31.4 billion ($39.3 billion), slightly ...

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

We recently compiled a list of the 10 Companies Jump on Better Earnings, Outlook. In this article, we are going to take a ...

Johnson & Johnson (NYSE: JNJ) has gone big early doors this year in the world of pharma M&A. The US healthcare giant ...

Astex Pharmaceuticals has been celebrating a very successful first 25 years following a visit from Science minister Patrick ...

Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...

GSK’s lead in vaccines is a cause for concern after mixed political signals in the US, with ardent vaccine sceptic Robert F Kennedy Jr vowing a clampdown on the pharmaceutical industry, which partly ...

London stocks nudged higher in early trade on Wednesday as investors mulled disappointing US tech results and continued to ...